Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antidepressant
Biotech
Supernus links depression drug to fast responses in ph. 2 trial
Supernus linked its mTORC1 drug to improvements in MDD, pointing to one possible path forward as it heads toward phase 2b data in another indication.
Nick Paul Taylor
Oct 18, 2024 9:17am
J&J's oral add-on aces phase 3 in major depressive disorder
May 29, 2024 11:55am
NRx keeps antidepressant's blockbuster hopes alive despite flop
Apr 30, 2024 11:16am
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Apr 23, 2024 10:44am
Eliem axes depression drug, lays off 55% of team to stretch cash
Feb 10, 2023 6:00am
Relmada rails against 'implausible' phase 3 depression data
Dec 8, 2022 8:55am